


PATENT



I hereby certify that this correspondence is being deposited  
with the United States Postal Service with sufficient postage  
as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on July 29, 2003.

  
Stephen A. Slush, Reg. No. 43,924

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 09/700,669  
Applicants : Bernt Sweder VAN ASBECK and Johannes Josephus Maria MARX  
Filed : January 3, 2001  
Title : USE OF A NUCLEIC ACID-BINDING CHEMOTHERAPEUTIC AGENT, AND A  
PHARMACEUTICAL COMPOSITION  
  
TC/A.U. : 1636  
Examiner : James S. Ketter  
  
Docket No. : 30394-1041

Commissioner for Patents  
United States Patent and Trademark Office  
PO Box 1450  
Alexandria, Virginia 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(c)**

S I R :

Pursuant to 37 C.F.R. §§ 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. § 1.56, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO 1449 submitted herewith. A copy of each of the listed references is also enclosed.

Although the information submitted herewith may be "material" to the Examiner's consideration of the subject application, this submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before the mailing date of either:**

- (1) A final office action under § 1.113 or
- (2) A notice of Allowance under § 1.311, whichever occurs first.

Applicant elects the option to pay the fee set forth in 37 CF.R. § 1.17(p) for submission of an information disclosure statement under 37 CF.R. § 1.97(c). (\$180) Attached is a check for \$180. If any additional fees are required, authority to charge the fee is given to Deposit Account No. 13-4213.

Respectfully submitted,



Stephen A. Slusher, Reg. No. 43,924  
Direct line: (505) 998-6130

Enclosures: PTO Form 1449;  
Copy of Reference

Peacock, Myers & Adams, P.C.  
Attorneys for Applicant  
P.O. Box 26927  
Albuquerque, NM 87125-6927  
(505) 998-1500  
FAX (505) 243-2542  
**Customer No. 005179**

Please type a plus sign (+) inside this box




PTO/SB/08B (10-96)

Approved for use through 10-31-99. OMB 0651-003

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  				<b>COMPLETE IF KNOWN</b>	
				Application Number	09/700,669
				Filing Date	January 3, 2001
				First Named Inventor	VAN ASBECK, et al.
				Group Art Unit	1636
				Examiner Name	J.S. KETTER
Sheet	1	of	1	Attorney Docket Number	30394-1041

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		REMICK, S.C., et al., "Continuous Infusion Bleomycin in AIDS-Related Kaposi's Sarcoma," <i>J of Clinical Oncology</i> , Vol. 12, No. 6, pp 1130-1136 (June 1994)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[G:\ANNETTE\L&S-VanAsbeck-1449.PTO.doc]

<sup>1</sup> Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.